Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCN03: HIV-1 Vaccines ChAdOx1.HTI, MVA.HTI, and ConM SOSIP.v7 in ART-Suppressed Individuals
NCT05208125Phase 1Completed
- Sponsor
- IrsiCaixa
- Start
- Mar 2022
- Primary completion
- Mar 2022
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ChAdOx1.HTI, MVA.HTI and ConM SOSIP in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by IrsiCaixa. Primary endpoints: Local IMP-related Adverse Events of Grade 3 and 4 at 30 weeks, Systemic IMP-related Adverse Events of Grade 3 and 4 at 30 weeks and 1 more. Started Mar 2022; status: completed.
02
Drugs
ChAdOx1.HTIMVA.HTIConM SOSIP
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05208125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208125.